Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onradivir PK in severe kidney impairment
NCT06248567Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of anlatrelvir in Influenza A virus infection (IAV) (2 arms), sponsored by Raynovent Biotech. Primary endpoints: Maximum observed plasma concentration and Area under the concentration-time curve from time zero to last time of quantifiable concentration. Started Jan 2024; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT06248567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06248567.